PTSD can be challenging to diagnose and treat as there is no objective measure to confirm a diagnosis. Trugenomix Health is developing the first genomic blood test to accurately diagnose PTSD. An objective genomic blood test for PTSD will result in early diagnosis, early intervention, improved clinical decisions, and improved patient outcomes.
Early diagnosis leads to early intervention and decrease symptoms
Genetic information facilitates personalized therapy and leads to improved outcomes
Early intervention and personalized therapy leads to reduced remission and lower healthcare costs